TIMKEN CO — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TIMKEN CO filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $80.10M | Feb 28, 2014 |
| FY2013 | Dec 31, 2012 | $107.40M | Feb 28, 2014 |
| FY2013 | Dec 31, 2011 | $124.40M | Feb 28, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.58B | Feb 13, 2026 |
| FY2024 | Dec 31, 2024 | $1.07B | Feb 20, 2025 |
| FY2024 | Sep 30, 2024 | $1.13B | Feb 20, 2025 |
| FY2024 | Jun 30, 2024 | $1.18B | Feb 20, 2025 |
| FY2024 | Mar 31, 2024 | $1.19B | Feb 20, 2025 |
| FY2024 | Dec 31, 2023 | $1.09B | Feb 20, 2025 |
| FY2024 | Sep 30, 2023 | $1.14B | Feb 20, 2025 |
| FY2024 | Jun 30, 2023 | $1.27B | Feb 20, 2025 |
| FY2024 | Mar 31, 2023 | $1.26B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.08B | Feb 26, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $296.10M | Feb 16, 2023 |
| FY2022 | Sep 30, 2022 | $322.80M | Feb 16, 2023 |
| FY2022 | Jun 30, 2022 | $341.80M | Feb 16, 2023 |
| FY2022 | Mar 31, 2022 | $327.40M | Feb 16, 2023 |
| FY2022 | Dec 31, 2021 | $233.10M | Feb 16, 2023 |
| FY2022 | Sep 30, 2021 | $267.90M | Feb 16, 2023 |
| FY2022 | Jun 30, 2021 | $302.30M | Feb 16, 2023 |
| FY2022 | Mar 31, 2021 | $299.20M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $237.00M | Feb 15, 2022 |
| FY2021 | Sep 30, 2020 | $263.70M | Feb 15, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $288.40M | Feb 13, 2026 |
| FY2024 | Dec 31, 2024 | $71.20M | Feb 20, 2025 |
| FY2024 | Sep 30, 2024 | $81.80M | Feb 20, 2025 |
| FY2024 | Jun 30, 2024 | $96.20M | Feb 20, 2025 |
| FY2024 | Mar 31, 2024 | $103.50M | Feb 20, 2025 |
| FY2024 | Dec 31, 2023 | $58.70M | Feb 20, 2025 |
| FY2024 | Sep 30, 2023 | $87.90M | Feb 20, 2025 |
| FY2024 | Jun 30, 2023 | $125.20M | Feb 20, 2025 |
| FY2024 | Mar 31, 2023 | $122.30M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $97.20M | Feb 26, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $540.60M | Feb 13, 2026 |
| FY2024 | Dec 31, 2024 | $113.00M | Feb 20, 2025 |
| FY2024 | Sep 30, 2024 | $146.30M | Feb 20, 2025 |
| FY2024 | Jun 30, 2024 | $167.20M | Feb 20, 2025 |
| FY2024 | Mar 31, 2024 | $184.60M | Feb 20, 2025 |
| FY2024 | Dec 31, 2023 | $119.20M | Feb 20, 2025 |
| FY2024 | Sep 30, 2023 | $149.60M | Feb 20, 2025 |
| FY2024 | Jun 30, 2023 | $200.70M | Feb 20, 2025 |
| FY2024 | Mar 31, 2023 | $187.60M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $127.00M | Feb 26, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $41.40M | Feb 14, 2020 |
| FY2018 | Dec 31, 2018 | $37.30M | Feb 15, 2019 |
| FY2017 | Dec 31, 2017 | $35.30M | Feb 15, 2018 |
| FY2016 | Dec 31, 2016 | $31.80M | Feb 21, 2017 |
| FY2015 | Dec 31, 2015 | $32.60M | Feb 24, 2016 |
| FY2014 | Dec 31, 2014 | $38.80M | Mar 2, 2015 |
| FY2013 | Dec 31, 2013 | $46.10M | Feb 28, 2014 |
| FY2012 | Dec 31, 2012 | $52.60M | Feb 13, 2013 |
| FY2012 | Dec 31, 2011 | $49.60M | Feb 13, 2013 |
| FY2012 | Dec 31, 2010 | $49.90M | Feb 13, 2013 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $748.30M | Feb 13, 2026 |
| FY2024 | Dec 31, 2024 | $187.50M | Feb 20, 2025 |
| FY2024 | Sep 30, 2024 | $189.70M | Feb 20, 2025 |
| FY2024 | Jun 30, 2024 | $184.10M | Feb 20, 2025 |
| FY2024 | Mar 31, 2024 | $190.70M | Feb 20, 2025 |
| FY2024 | Dec 31, 2023 | $189.50M | Feb 20, 2025 |
| FY2024 | Sep 30, 2023 | $179.60M | Feb 20, 2025 |
| FY2024 | Jun 30, 2023 | $184.90M | Feb 20, 2025 |
| FY2024 | Mar 31, 2023 | $186.80M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $167.30M | Feb 26, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $554.30M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $475.70M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $545.20M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $463.80M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $387.30M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $577.60M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $550.10M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $332.50M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $236.80M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $403.90M | Feb 15, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $178.40M | Feb 16, 2023 |
| FY2022 | Dec 31, 2021 | $148.30M | Feb 16, 2023 |
| FY2022 | Dec 31, 2020 | $121.60M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $140.60M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $112.60M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $104.70M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $137.50M | Feb 15, 2019 |
| FY2017 | Dec 31, 2015 | $105.60M | Feb 15, 2018 |
| FY2016 | Dec 31, 2014 | $126.80M | Feb 21, 2017 |
| FY2015 | Dec 31, 2013 | $133.60M | Feb 24, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.68B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $6.41B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $6.54B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $5.77B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $5.17B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $5.04B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $4.86B | Feb 16, 2021 |
| FY2019 | Jan 1, 2019 | $4.54B | Feb 14, 2020 |
| FY2019 | Dec 31, 2018 | $4.45B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $3.40B | Feb 15, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Jan 1, 2019 | $2.90B | Feb 14, 2020 |
| FY2019 | Dec 31, 2018 | $2.80B | Feb 14, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.18B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.83B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $2.58B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $2.27B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $2.29B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $2.15B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.87B | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $1.58B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.44B | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $1.28B | Feb 15, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.49B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.38B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $1.37B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $1.10B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.02B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $1.05B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $993.70M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $960.50M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $511.80M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $357.50M | Feb 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.68B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.49B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $2.23B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.93B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $1.62B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $1.34B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.91B | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $1.63B | Feb 14, 2020 |
| FY2018 | Jan 1, 2018 | $1.41B | Feb 15, 2019 |
| FY2019 | Dec 31, 2017 | $1.41B | Feb 14, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $364.40M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $373.20M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $418.90M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $331.60M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $257.10M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $320.30M | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $209.50M | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $132.50M | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $121.60M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $148.80M | Feb 15, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.90B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.05B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $2.15B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.92B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $1.42B | Feb 16, 2023 |
| FY2020 | Dec 31, 2020 | $1.44B | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | $1.71B | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $1.65B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $856.90M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $640.00M | Feb 15, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 13, 2026 |
| FY2024 | Dec 31, 2024 | 1 | Feb 20, 2025 |
| FY2024 | Sep 30, 2024 | 1 | Feb 20, 2025 |
| FY2024 | Jun 30, 2024 | 1 | Feb 20, 2025 |
| FY2024 | Mar 31, 2024 | 1 | Feb 20, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Feb 20, 2025 |
| FY2024 | Sep 30, 2023 | 1 | Feb 20, 2025 |
| FY2024 | Jun 30, 2023 | 1 | Feb 20, 2025 |
| FY2024 | Mar 31, 2023 | 1 | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | 1 | Feb 26, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 13, 2026 |
| FY2024 | Dec 31, 2024 | 1 | Feb 20, 2025 |
| FY2024 | Sep 30, 2024 | 1 | Feb 20, 2025 |
| FY2024 | Jun 30, 2024 | 1 | Feb 20, 2025 |
| FY2024 | Mar 31, 2024 | 1 | Feb 20, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Feb 20, 2025 |
| FY2024 | Sep 30, 2023 | 1 | Feb 20, 2025 |
| FY2024 | Jun 30, 2023 | 1 | Feb 20, 2025 |
| FY2024 | Mar 31, 2023 | 1 | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | 1 | Feb 26, 2024 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $98.30M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $96.10M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $94.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $91.70M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $92.20M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $87.00M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $84.90M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $85.70M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $83.30M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $81.60M | Feb 15, 2019 |